calcium dobesilate has been researched along with heparitin sulfate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Misra, MC | 1 |
| Bollin, R; Haller, H; Menne, J; Njau, F; Schenk, H; Shushakova, N; Wulfmeyer, VC | 1 |
| Chernobrivaia, E; Haller, H; Kiyan, Y; Rong, S; Schultalbers, A; Shushakova, N; Tkachuk, S | 1 |
1 review(s) available for calcium dobesilate and heparitin sulfate
| Article | Year |
|---|---|
Drug treatment of haemorrhoids.
Topics: Administration, Rectal; Calcium Dobesilate; Flavonoids; Ginkgo biloba; Hemorrhoids; Heparitin Sulfate; Humans; Phytotherapy | 2005 |
2 other study(ies) available for calcium dobesilate and heparitin sulfate
| Article | Year |
|---|---|
Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice.
Topics: Animals; Binding Sites; Calcium Dobesilate; Cell Movement; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelial Cells; Heparitin Sulfate; Humans; Kinetics; Mice; Mice, Inbred NOD; Protein Binding; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate.
Topics: Animals; Calcium; Calcium Dobesilate; COVID-19 Drug Treatment; Endothelial Cells; Heparitin Sulfate; Humans; Mice; Protein Binding; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virus Attachment | 2022 |